Sinovac Biotech has reported that its Covid-19 vaccine, CoronaVac, obtained approval from the Health Bureau of the Government of the Hong Kong Special Administrative Region of the People’s Republic of China for usage in children of the age six months to three years. 

The consensus interim recommendations on Covid-19 vaccine use in children aged six months or above in Hong Kong were released by the Scientific Committee on Vaccine Preventable Diseases and the Scientific Committee on Emerging and Zoonotic Diseases under the Centre for Health Protection of the Department of Health.

The approval is based on clinical trials and studies of Covid-19 inoculation in children and adolescents in the region.

In individuals of this age group, the vaccination schedule approved for use is the same as those in older children. 

Children aged six months to below three years can receive three doses of vaccines. The initial two doses can be given at a gap of 28 days while the third dose can be administered a minimum of three months following the second vaccine dose. 

Furthermore, no restriction is imposed on vaccine usage in immunosuppressed children.

In February, the vaccine received emergency use authorization (EUA) for minors and adults aged over three years in Hong Kong. 

CoronaVac has so far received approvals in over 60 countries and regions globally. 

Last year, Sinovac commenced the Phase III clinical trials of CoronaVac in children aged six months to 17 years. 

Initial data demonstrated that the vaccine possesses a good safety and immunogenicity profile. 

No severe adverse reactions were observed six months following two vaccination doses in children aged six to 35 months.

In July, the Brazilian Health Regulatory Agency (Anvisa) granted EUA for CoronaVac to children aged three to five years.